Flotek Industries, Inc. (FTK) Earnings Call Transcript & Summary

August 25, 2022

New York Stock Exchange US Materials Chemicals special 36 min

Earnings Call Speaker Segments

Jeffrey Robertson

analyst
#1

For fireside with John Gibson, who is Chairman and CEO of Flotek Industries who is Chairman and CEO of Flotek Industries. Flotek is a company that provides chemistry solutions to the oil and gas industry to consumers and then also has a data analytics segment, which primarily serves virtually all parts of the energy value chain. I would -- before we get started, I would like to remind people that today's discussion may include forward-looking statements and I will refer viewers to participants to Flotek's disclosures in its SEC filings and on its corporate web page under the Investors section or the Media & Presentations section for the company's most recent corporate presentation, which was posted on August 9 in connection with second quarter earnings. So with a little bit of housekeeping out of the way, John, thank you for joining us today.

John Gibson

executive
#2

Good to be here.

Jeffrey Robertson

analyst
#3

So as I said, Flotek reported second quarter numbers on August 9, which started to show the initial revenue contribution from the ProFrac supply agreement, which was signed in early February and went into effect on April 1. Reported revenues were $29.4 million, 128% up from the first quarter of '22 and over 220% higher than second quarter of 2021, driven by the combination of the increased business with ProFrac, but also importantly, increased business with other customers, not ProFrac or the transaction side of the business, which also increased substantially in the quarter. At the end of the -- the average fleet count with ProFrac was about 8 in the second quarter. It could be about 16 in the third quarter and probably get to somewhere in the early 30s, which is the contract amount in the first part of 2023. So John, let's start with just questions that we heard on the earnings call. You and Ryan suggest or indicated that servicing additional frac crews have gone flawlessly. Can you talk about the challenges you're overcoming in dealing with to continue to ramp up again, serve the incremental crews in the third and fourth quarter and ultimately in '23?

John Gibson

executive
#4

Of course, I will say when we said flawless, I'd probably make it asymmetric flawless, we were absolutely focused on flawless execution for ProFrac, our customer and for our transactional customers. And so on the forward side of what we were doing, I think we did a great job of getting it to the field, getting it to the customer of our customer, making sure that the ultimate producer was not impacted by the ramp-up. And so I think we did a great job with a great partner, ProFrac. However, on the back side, getting the things back to our plant, refilling them and sending them out again. we're still improving, right? So I'd say some of the margin that we will anticipate in the future is going to come from handling both sides of the transaction, both delivery then returning and sending out again. And so I'd say in Q2, we did a great job of delivering. And in Q3, we'll be both delivering and returning. And it's that logistics side of getting it back where we'll lead margin. And so that's the part where I think we're super focused on, and Ryan Ezell and his team are doing a great job on making sure that we have the full approach to that, Jeff. And so -- it's interesting and to ramp up this big. You have to remember, we went, as you stated in the beginning, we did about 19 million pounds of chemistry in 2021, and we did over 40 million pounds of chemistry in Q2. So that's twice the volume in Q2 that we did last year. We did spend money to purchase the ISOs and the in order to get the equipment and hauls to get it to location, and that's our onetime cost. And now we're actually becoming more efficient. We have in-basin delivery where we're staging it there so that as we've learned, we don't want to haul all the equipment back to Oklahoma. We want to make it a few miles instead of hundreds of miles. There's margin and all of that. So a lot going on to wrap up like this.

Jeffrey Robertson

analyst
#5

John, we've talked about the agreement with ProFrac on a crew basis. But it's actually a -- it's a contract to deliver a volume of chemistry to them to meet their need -- to meet needs set out in the contract. At the beginning or at the initial stages of the contract, how do volumes that you all are delivering to ProFrac for the crews that you're working on compare to what was laid out in the assumptions that were put into agreement?

John Gibson

executive
#6

Another very good question, Jeff, and 1 that is morphing or changing at the moment, when we first initiated the contract, the majority of the industry was still in trying to minimize cost. And so if you take a look at how ProFrac and Flotek estimated the volumes because you're correct, it's a volume contract. We looked at sort of what would be the minimum amount that they would use because that's all really ProFrac wanted to guarantee and I can understand that being the case. And it's way more complicated than a single number. It's actually volumes based on each basin and what fluids are needed in those basins. There's a lot of difference between the Permian and East Texas and the Eagle Ford and the Marcellus. And so it's specific numbers and the number of fleets anticipated there. And so at the current time, too long an explanation here. But at the current time, the volumes are materially above what we had originally calculated for 2 reasons. One is we did do it on a minimal basis. Number 2 is they've shifted from lowest cost to maximum AUR maximum production and IP and the least decline. And so they're beginning to worry a lot more about reservoir dynamics, and that's where Flotek excels is our [indiscernible] is designed to maximize production and maximize recovery. That's where we think we have the best solutions. And we're beginning to see that value desired by the producers. And as a result, we're seeing our higher margin components increase in each 1 of the fleets. And I think that's going to become a bigger part of the portfolio for each pad, each well as we go into 2023 and beyond because people are really focused back now on maximizing recovery and increased production on a per well basis. It's not just the cost base industry any longer.

Jeffrey Robertson

analyst
#7

I'm going to follow up with that. So you talked about into 2023, which is still 4 months away, but I know producers are thinking about their capital programs and activity levels far out into the future. Do you have a lot of line of sight on the types of chemicals that producers are trying to buy that you'll continue to see some mix of maybe those chemicals that you have a chance to make a higher profit on versus just the base level of friction reducer type chemicals?

John Gibson

executive
#8

We do. I mean I think we see surfactants becoming more important. Our CnF product line complex nanofluid, the need for bio side and how we use bio side. And in some cases, we may reduce the volume but increase our margin. Jeff, I mean there are some solutions where when you look at that [indiscernible] answer, you're better off to use less of something. But in that case, we may have better margin on less chemicals. So we're trying to optimize margin and as well as be the greenest chemistry company. And it's not always intuitive, it's what's the greenest, it's not just try to pump the most. It's pumped the best and get the best result.

Jeffrey Robertson

analyst
#9

The -- we talked about this before, but it seems to come up that the contract does contain some margin protection for the friction reducer chemicals, which I think you've described in the past has typically been a loss leader for the industry. And I guess along what we were just talking about, just has the mix of chemicals changed very much from what you thought you were signing up for in February. Maybe it's partly producer-driven like you mentioned. But is there a greater adoption of some of the chemical solutions Flotek is providing as well that's behind that?

John Gibson

executive
#10

I probably should get Ryan or James Silas, our Head of Research, to do 1 of these chats with you 1 day on just friction reducer because friction reducer or it's polyacrylamide are the bread and butter of the chemistry industry, people don't realize just how much horsepower it would be required if you didn't have the ability to reduce friction in order to get the downhole pressures that are desired, you'd lose a lot of it on the surface, it would mean having to go in and increase horsepower dramatically. So in order to reduce horsepower, you reduce friction as you begin to inject. And so friction reducer is not all the same. And so when we say friction reducer, it makes up a large portion of the portfolio, but there is numerous kinds of friction reducers and people now are becoming serious about choosing friction reducers that are prescriptive for the problem that they have. And so there's varying margin even in the prescriptive FRs, right? So we can we can have different FRs for different basins and different pads. That gives us margin expansion opportunity as well. But by and large, people are trying to sell FR in order to win the clay stabilizers, the buy sides, the surfactants. And it -- and then what we did with ProFrac was to ensure that we didn't have a huge volume that was negative to us like other people with a loss leader. So we put a fixed margin in. So the great reason that, that causes alignment is that from a margin perspective, I don't care how low the volume gets. If we can choose FRs that they can use less of, we still make a good margin on that, and it doesn't become a problem for us. So I think that's great alignment with the customer. But there's a lot of variance in it, right? There's different FRs, different margins for us there. And it has proved to be something that will be accretive to us as we go forward because we're not losing money on a day-to-day volume on FR. But don't think of it as a single product, it's varies a lot by basin, a lot by pad and a lot by reservoir.

Jeffrey Robertson

analyst
#11

The Flotek spends a lot of time on technology, obviously, as a chemistry company. But my understanding is you all can as go for a certain formation and help the customer design the chemical solution, which will be best suited to that formation, whether it's in West Texas or Louisiana or the Marcellus. Are you seeing more producers looking to you for those types of answers?

John Gibson

executive
#12

We do a lot of that work, Jeff. It's -- I don't want to get too technical, but in every reservoir is made up of different rocks, different petrology -- and so the chemistry that you inject is going to react differently based on the fluids that are in the rock based upon the mineralogy of the rocks, what the chemistry of the rocks are, diagenesis, which is the precipitation of material in the poor space. How are you going to interact with that? Which clays are there? Are we expanding the clays, are we trying to prevent expansion. And so in every case, you have to look at the chemistry, and you not only have to look at the chemistry, you have to look at the interaction between different chemicals that you're injecting. So I say this often [indiscernible] is much like a patient, if you were a doctor, and you're prescribing medication for it to try to make the patient better. Often, wells have many doctors looking into them, and you can have an interaction between 2 medications, it kills a patient is absolutely true in the world of chemistry. And so we have to take a look at the patient, understand what others might be prescribing for the patient, but also understand the patient, which is the reservoir and then say what is going to be in the best interest of optimizing the health of that reservoir, which would be the ultimate recovery as well as the initial production and the minimization of that decline curve.

Jeffrey Robertson

analyst
#13

We -- I believe on the call, you all talked about the ProFrac or revenue from the ProFrac contract in the context of roughly $500,000 to $600,000 per fleet per month. That's a relatively easy way to think about services, but can you just talk about some of the moving parts that go into how those numbers are put together?

John Gibson

executive
#14

Sure. I mean every fleet, the -- they're working directly with the producer to determine what fluids are necessary and what horsepower is required and the interaction of the reservoir. When you look at that, we're having to try to do -- and this will get better with time is how do we report to our shareholders what we're doing. And so I think an average amount of chemical per fleet, probably not a bad metric to use, but you've got to realize it varies dramatically between East Texas, the Permian, the Marcellus, the Bakken. It's every base in Delaware, you're using different volumes of chemicals at different depths and different reservoirs. And so when you look at any volume we might give you on an average basis, there's quite a lot of variance between those. And so now you have a mix issue, right? Each quarter, like talked about in many, many businesses. So it's that mix of basins and what we do, I think rather than breaking it all out, we'll probably try to stay to just chemical pounds per fleet, per month or pounds per fleet per quarter. and look at that. And you can also extrapolate those to say that those are pounds per fleet for even our transactional business, and we're growing the number of fleets there as well. And so it's a good proxy. And so -- and then the other 1 is how many fleets are we serving? And we're growing to where our goals to be a significant portion of the overall fleet count, and that would be the combination of the ProFrac fleets plus the other fleets that we're serving their competitors to ProFrac because it's not exclusive contract, we intend to be the chemistry company in oil and gas, optimizing production for every producer and every 1 of the pumping companies.

Jeffrey Robertson

analyst
#15

In the sense of the different basins that you produce and I know obviously, you drill a different well in each basin based on the depth and reservoir pressure and link the lateral and a whole host of inputs. Are there -- are some basins for the Flotek chemistry suite more profitable than others, just given what's needed and what operators are doing in those basins at the moment?

John Gibson

executive
#16

It's another good question. There are some reservoirs that you don't add as much value to as others, okay? And so it gets to be pretty vanilla as to what you pump. You want -- That's how you build a relationship with somebody across the whole of their fleet is making sure you're working on their vanilla fleets and they're complex fleets that have greater profitability and greater margin. But yes, there are well that just take the basics. There are customers that just take the basics, and then you have customers that are trying to optimize the EUR, the estimated ultimate recovery. You have some that are trying to minimize cost. So it's a mix. We prefer the customers that are more scientific, that are trying to base their value on recoveries and proper sustainability metrics, the reservoir really committed to green, those are the sweet spots for us, better margin, better alignment with objectives than 1 where it's vanilla and there's less concern about ESG.

Jeffrey Robertson

analyst
#17

You announced on August 9 in a separate press release in the earnings release that Flotek had agreed with ProFrac to provide up to 20 of your JP3 Varex analyzers. I know you all have used them on some of their equipment to help them monitor their depth of gas and so they can manage their equipment. Is this a way -- or I guess can you first talk about the timeline of deploying these units into the field?

John Gibson

executive
#18

Well, I think they're re-outfitting the units with the Verax analyzers sort of limited to the speed at which they're bringing them in and refurbishing them as they come in from the field for maintenance, R&M and then it gets sent back out. I think they intent to get them deployed as quickly as possible. So this is more of just not interfering with production operations, but getting the mole. It's a spectacular solution in the elimination of the vast majority of diesel in the field. You can take out 50% to 70% of the daily diesel use. That's a huge reduction of Co2, big cost reduction for the producers themselves. A bit of conflict because you've got some pumpers that are actually charging administrative costs on diesel. And now you're moving over to gas. And so there's a bit of a margin trade that occurs there as you switch over some of that. We're getting a bit of that margin, but we're eliminating a large amount of cost by deploying the analyzers. These analyzers are going to be, I think, have the opportunity to be prolific across everything that wants to use field gas that has variants in the BTU that needs a quality control mechanism. So that you don't damage equipment by either putting in a shut off or you regulate it through some sort of regulators so that we can normalize BTU so that you don't have the potential for damaging equipment. Nothing is worse now than damaging a piece of equipment because replacing it the lead time on that could be quite long. And you don't want to be pulling equipment out of production today for months while you're waiting on parts. And it's -- this is a critical element, switching to gas. Gas compressors, it's not just the green. It's going to be anything that's producing power in the field. I was in a conversation recently, there's a new company coming to the U.S. to do bitcoin mining and the volume of gas that they need is enormous, and they want to co-locate the bitcoin mining with stranded gas. So they can have availability to gas that will be at favorable pricing in extremely large volumes because they too want to have a green offering. And so how do you do that and supply the gas. I mean, Caterpillar is a big part of this, too. They're putting in a lot of these big fuel turbines for bitcoin mining. That's another place where JP3 could make a big difference as well.

Jeffrey Robertson

analyst
#19

Is it one way to think about the rollout, the initial rollout of the units with ProFrac, is this kind of a proof of concept for the uptake of those units across some of these new other opportunities that you outlined?

John Gibson

executive
#20

Yes. The great part of a partnership, like we have with ProFrac is that they're willing to talk about what we're doing together. And it's really hard often to get somebody just getting value out of something because they want a competitive advantage to go out and do a white paper or marketing announcement with you. The beauty of ProFrac is that they are willing to make the necessary changes and then talk about the value creation that's occurring. And so the rollout of this, I think, is critical to the adoption by others because you're going to see somebody that's willing to talk about how much value is being created, how much greenhouse gas is being eliminated, what the value is to our industry and the improvement of our image and our concentration on being more sustainable than I think that the Verax analyzers are 1 component in our industry's commitment to greater sustainability. And I'm excited that we're bringing 1 element of it.

Jeffrey Robertson

analyst
#21

Let's tip gears toward transactional chemistry [indiscernible] or I guess people can think about it as third-party non-ProFrac chemistry technology customers. As I said earlier, that jumped significantly in the second quarter in terms of that business. What were the primary drivers of that growth? And is it something that's repeatable? Is it something that as the DUC inventory goes down, people start need to drill more wells and need more Flotek chemistry?

John Gibson

executive
#22

Actually, we've been working on that business before we got the ProFrac contract. And we felt like we could sustain double-digit CAGR on it throughout the 2023 -- 2022. And I think we proved our ability to do that in Q2, with how much growth we had there. That has to do with looking for customers that have alignment with greater chemistry, looking for customers that value improved production. And so we have several of those, and that continues to grow. And that's with us -- and it's an interesting market in which we're selling both to pumpers, but also to end customers. And so we really understand very well what the end customer desires, what the producer desires, and then we're going back and working with ProFrac and other pumpers to say, here's the chemistry that achieves the customer's goal, right? And it's not just low-cost stimulation. It's actually how does that impact the reservoir with the design. So we're working directly with those customers. The exciting things are like for instance in our labs in Oklahoma. A lot of this has to do with the interaction with water. And so people send us their produced water so that we know the exact chemistry of the water that we'll be interacting our chemicals with in that reservoir. We use those waters to do the analysis. We actually use cores and have roller Rothmans and other things in order to get to the same temperatures than so that we can do the analytics on it. And that transactional business looks to be really strong and will continue to grow, and I've got confidence in it throughout the rest of this year. And we were betting the whole company on that without the ProFrac contract and we still think we have a really strong offering there.

Jeffrey Robertson

analyst
#23

I know you -- I think you all changed the way you approach that business in either 2021 or maybe even when you joined Flotek. So is it just that second quarter, you had industry activity and the fruits of those efforts to change how you all market that business or market Flotek to those customers all really started to hit home?

John Gibson

executive
#24

I mean when I joined, I give a lot of credit to Ryan Ezelle and the team there. It's -- what we did was we drank a lot of coffee, and we were selling 1 product, which was really just CnF. And in a down market, having the outside of core products is not a great place to be because you're the first to be eliminated from the PO. And so if you're nice to have or wish we had, but not absolutely necessary, then you have a sales issue and you see a tremendous decline in your revenues. So we decided we want to be in the whole of the chemistry business and provide the core products and then upsell when the opportunity existed into the value-add products with the higher margin. I think that's what was transformational for the company was saying we're a full-service chemistry company for stimulation, not a 1 chemical additive to another chemistry company for the job. So we're now -- you're capable of calling us now, we'll provide the full suite of chemistry over your stimulation job. It's not just an additive or a single product. And I think that insulates us along with the ProFrac contract from cycles in the industry. I think we're now a full cycle chemistry company that's got a robust profile for revenue for a decade without having the dips that you would see normally in a specialty chemical value add, not core, necessarily that somebody might get rid off here in a downturn.

Jeffrey Robertson

analyst
#25

We -- we talked about the ProFrac agreement transaction on chemistry. I think to supply the ProFrac volumes, it requires about 50% of Flotek's existing chemistry capacity. In the second quarter, and you all have talked about it maybe in the third and in the fourth. There are some costs associated with ramping up activity to serve increased volume commitments under the ProFrac agreement. Can you just talk about what some of those costs are? And how controllable they are?

John Gibson

executive
#26

That's a good question. We've actually made the transition to the ProFrac contract where we are so far with basically no additional hit. We're still roughly at the same head count. So -- and I think we can get to the full complement of products for ProFrac with less than a 5% change in our headcount. Now that's pretty small. We've got about 140 employees, so you're looking at adding 7 to 10, okay? And if we added another shift in Marlow, we could double the capacity up there pretty easily or say 80% more than what we have today. And so what is it that we need to do? Our cost in Q2 where mobilization units and trucking to get the chemistry from the plant to the location, we didn't have enough, okay fundamentally. I think I'll get the numbers are also right and correct. But I think we had 15 or 20 ISOs available to us. And in order to do what we did, it took over 100. So what the biggest task was finding ISOs and then getting the proper telemetry on them because ProFrac is a very forward-leading tech company. They don't want just ISOs that you're doing strapping home. They actually want digital measurements of watching the tank. So we had to find not just ISOs, but telemetry enabled ISOs. And so we went from 2 dozen to over a 100 that was the issue and the cost there, not the plant. Now the plant, I believe, we can double the volumes that we have to date without having any additional costs. We don't need more tanks. We don't need more hoses, no more forklifts, no more blenders. I mean we are -- we have an outstanding plan to scale to this contract. And if we do need to add more capacity, we can add a shift. And so if we ran multiple shifts there, I mean, I look at that plant and go, I think we could supply 270 fleets if we had to. And so not it's just a matter of getting that high market share.

Jeffrey Robertson

analyst
#27

Does deploying some of the equipment that you've already put out and I presume will put out in the second quarter or the second half of the year. Will that help translate into improved margins at some point later this year or as you think about going into 2023, is that a component of getting toward the goal of positive EBITDA and having EBITDA in 2023?

John Gibson

executive
#28

Every activity in the company today is focused on us getting to positive adjusted EBITDA and Jeff, I mean everything. And so we believe we have enough revenue next year that you can calculate based upon the ProFrac contract, you could take our transactional revenue from Q2 and annualize it. You could put some adder on there for our industrial chemicals and the Verax analyzers you'd get to a pretty good number. I mean, it'd be at least double what we'll do this year and in 2023. But doubling the revenue is not as important right now to me as it is getting to free cash flow. And so we -- what we're doing is we're saying, what is it that we're doing that we need to be more efficient at and where is it that the margin might have leaked out or we can create margin. And we have exercises to create more margin by our choice of products that we're delivering that where we've got lower cost and greater spread on the price. We're also the logistics piece -- we worked really hard to get chemicals to the field on time in Q2, and we're going to work really hard at Q3 and Q4, minimizing the cost of any returns back to us and making sure that, that doesn't erode any margins. So imagine we were shipping things back to Marlow. Now we've got a strategy of having in-basin areas that we can hold the chemicals and move to the next pad to eliminate the trucking cost. So this is really about efficiency in returns, managing the products that go out, having a way of charging a restocking fee or something to make sure that we minimize the returns from customers. And I think there's a lot for us to expand our margins. And we can do it with the revenues that we're anticipating. We don't -- we should see more and more fall-through after we get through Q4 and we get ramped up to the majority of the contract.

Jeffrey Robertson

analyst
#29

John, as we started out, we talked about the second quarter kind of an inflection point with the initial revenue contribution from the new supply agreement and also the increase in transactional revenue. So Flotek is clearly in a very, very different place in August of 2022 than it was in August of 2021 or even January of 2021 before the supply agreement was announced. Between expanding the supply or the business with ProFrac and additional penetration with other customers, are there other opportunities that you're outlooking at conceptualizing to build value for Flotek that you can share?

John Gibson

executive
#30

Ask me 1 more time, partly to give me a little more time to thank, Jeff.

Jeffrey Robertson

analyst
#31

So in a different position that the company is in today, with the supply agreement ramping up with the customer penetration increasing, you're deploying JP3 analyzers across some of the ProFrac equipment. Are there other things that you're working on or like conceptually that we should be aware of and that you can share?

John Gibson

executive
#32

I appreciate you giving me a little bit of time to ponder there. Probably nothing too much to share, but I got to ask this question slightly differently at a talk a couple of weeks ago where they I was asked and the moderator, much like you asked the whole of the group, are your companies trying to be butchers and bakers. And every person in the room pretty much raised their hand and then he turned to me and he said, "is Flotek going to be a butcher and a baker". And I went, we're just going to be a baker. We're not going into the butcher business. We're a chemicals company. Jeff, I mean, fundamentally, we are a chemistry company. And I look at the Permian, I look at the unconventionals and how that's ramping up and the importance of that to the U.S. and energy security and delivery for the country. And you go, I think it's going to be robust for several years to come. And there's no reason for us to go out and take risk on something that's outside of the chemistry business. And so we're going to be a chemistry business. I don't think that there's any reason for us to get into the interpretation business or into the general software business or into a hardware business that's not directly related to chemistry. So if you saw us expand, expect us to expand into things that are molecular and chemistry and you can ponder what all those would be. But I mean, we're obviously looking at that. And if there's any kind of synergies that occur there, where it makes both of us more profitable, it's pretty exciting, but it really needs to be a molecules-based business. If we're going to prosper on it, we've got deep competency in chemistry, and that's where we're going to stay. We should know the rig I don't think I've got anybody here that could run a rig. We're not a pumping company. It's great to partner with people like ProFrac. We're not a bit company. We are a chemistry company, and that's what we're going to be going forward.

Jeffrey Robertson

analyst
#33

John, I think we'll leave it there for today. I would like to follow up with you and maybe have Ryan on 1 of these to help explain what some of these chemistries do and how they interact differently in different reservoirs and serve your customers' needs for better EUR and better economic performance, which I think at the end of the day is what will drive their uptake of what Flotek provides.

John Gibson

executive
#34

Well, we've got a phenomenal backlog going into next year. So I think our commitment to our shareholders, Jeff, is to engineer ourselves to be profitable. And we've got the critical mass of revenue. Now we just need the discipline to turn that revenue into profits. And that's where we're focused, and that's what we're going to try to deliver as we go into 2023.

Jeffrey Robertson

analyst
#35

John, thank you so much for your time today.

John Gibson

executive
#36

Thanks so much, Jeff.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Flotek Industries, Inc. transcript — plus 248,000+ transcripts from 12,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to Flotek Industries, Inc. earnings transcripts and 248,000+ others is available through the EarningsCalls.dev REST API. Plans from $24.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.